Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 1
Submit an article Journal homepage
203
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Impact of therapy on the development of second malignancies in essential thrombocythemia and polycythemia vera: Are we comfortable about this?

Luigi MarcheselliDepartment of Diagnostic, Clinical, and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
,
Aaron PolliackDepartment of Hematology, Hadassah University, Hospital and Hebrew University Medical School, Jeruslaem, Israel
&
Tamar TadmorHematology Unit, Bnai-Zion Medical Center, Haifa, Israel;Rappaport Faculty of Medicine, Technion, Institute of Technology, Haifa, IsraelCorrespondence[email protected]
Pages 6-7 | Published online: 07 Sep 2015

References

  • Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755–761.
  • Radaelli F, Onida F, Rossi FG, et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology (Amsterdam, Netherlands) 2008; 13:195–202.
  • Finazzi G, Ruggeri M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577–583.
  • Vannucchi MA, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev 2009;18:2068–2073.
  • Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011;118:6515–6520.
  • Fallah M, Kharazmi E, Sudquist J, et al. Higher risk of primary cancers after polycythemia and vice versa. Br J Haematol 2010;153:273–285.
  • Kissova J, Ovesna P, Penka M, et al. Second malignancies in Philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res 2014;5:248–2496.
  • Khanal N, Giri S, Upadhayay S, et al. Risk of second primary malignancies and survival of adult patients with polycythemia vera: a US population-based retrospective. Leuk Lymphoma 2016;57:129–133.
  • Masarova L, Cherry M, Newberry KJ, et al. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma 2016;57:237–239.
  • Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long–term survival in essential thrombocythemia. Leukemia 2014;28:2300–2303.
  • Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;23; 372:1670–1671.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.